NEW YORK (GenomeWeb News) – Horizon Discovery and biopharmaceutical firm H3 Biomedicine today announced a collaboration to identify and validate a panel of novel cancer drug targets.

The firms will partner to carry out experiments that seek to identify cancer genome targets. H3 will carry out early target discovery through pre-clinical research, and Horizon will use its drug discovery tools "to run alongside and support [H3's] discovery biology and chemistry assets and capabilities," the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.